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Zusammenfassung
Hintergrund: Ziel dieser Studie war es, die Hörfunktion 
von gynäkologischen Tumorpatientinnen unter den der-
zeit gängigen Chemotherapie-Schemata zu untersuchen 
und eine mögliche Ototoxizität der Chemotherapien ab-
zuklären. Patientinnen und Methoden: Es wurden insge-
samt 87 gynäkologische Tumorpatientinnen (darunter 
79% Mammakarzinom- und 14% Ovarialkarzinom-Patien-
tinnen) die mit derzeit gängigen Chemotherapie-Sche-
mata behandelt wurden, untersucht. Das Hörvermögen 
wurde sowohl subjektiv auf einer visuellen Analogskala 
abgefragt als auch mittels Reintonaudiogramm vor 
Chemotherapie, 9 und 18 Wochen nach Beginn der 
Chemotherapie und 3 Monate nach Beendigung der 
Chemotherapie getestet. Ergebnisse: Die Patientinnen 
waren zwischen 32 und 71 Jahren alt (im Durchschnitt 
53,5 ± 10,5 Jahre). Auf einer visuellen Analogskala (0 = 
kein Hörvermögen, 100 = exzellentes Hörvermögen) 
schätzten sich die Patientinnen im Durchschnitt mit 
einem Wert von 83,0 ± 17,2 vor Chemotherapie und 
84,8 ± 16,9 3 Monate nach Beendigung der Chemothera-
pie ein. In den Reintonaudiogrammen zeigte sich kein 
signifikanter Unterschied in den Hörschwellenwerten im 
Sprach- als auch im Hochtonfrequenzbereich zu allen 
Messzeitpunkten. Es gab keinen signifikanten Unter-
schied in den Hörschwellenwerten von Patientinnen mit 
und ohne platinhaltiger Chemotherapie. Zusammenfas-
sung: Ein Hörverlust bei gynäkologischen Tumorpatien-
tinnen unter den derzeit gängigen Chemotherapie-Sche-
mata ist unwahrscheinlich und es bedarf bei diesen 
Patientinnen keiner routinemäßigen audiometrischen 
Kontrolle.
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Summary
Background: Our objective was to assess the auditory 
function of gynaecological tumour patients who had 
 received cytotoxic agents and to determine their associ-
ated risk of ototoxicity. Patients and Methods: 87 pa-
tients who had undergone chemotherapy for gynaeco-
logical malignancies were investigated. Of these patients, 
79% had breast cancer, and 14% ovarian cancer. All of 
the patients had a subjective assessment of their hearing 
function on a visual analogue scale. Audiometric tests 
were performed before and at 9 weeks, 18 weeks and 
3 months after completion of chemotherapy. Results: 
The age of the patients ranged from 32 to 71 years 
(mean age of 53.5 ± 10.5 years). The average subjective 
rating of the patients’ hearing function was 83.0 ± 17.2 
before and 84.8 ± 16.9 3 months after completion of 
chemotherapy. No significant audiometric change at 
 either the speech hearing frequency range (0.5–2 KHz) or 
high frequencies was observed in the patients after 
chemotherapy. There was also no significant difference 
in the hearing threshold of the patients who had re-
ceived platinum analogue-based chemotherapy com-
pared to non-platinum analogue-based chemotherapy. 
Conclusion: Hearing loss is uncommon in patients 
treated with the typical gynaecological chemotherapy 
protocols. Hence, routine audiometric testing in these 
patients is not necessary.
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Introduction
Cancer still accounts for more deaths than heart diseases in 
people younger than 85 years of age [1]. Breast cancer for 
 example is the most common gynaecological malignancy 
 diagnosed in both American and German women [2, 3]. How­
ever, progress has been made in reducing the incidence and 
mortality rate of the cancer disease, as well as improving the 
survival rate of these patients [1]. The better outcomes of this 
disease may be due to the availability of better equipment for 
the early detection and diagnosis of cancer. It may also be 
 attributed to rapid changes in the recognization of risk factor 
patterns and the introduction of newer and better chemo­
therapeutic agents for treatments.
Chemotherapy is an effective treatment that may dramati­
cally improve cancer symptoms and the overall survival rate 
of the cancer patients. However, there is still some uncer­
tainty about whether the chemotherapy that is used to treat 
cancer patients can be employed in a way that ensures the 
preservation of the patients’ hearing. The issue of quality of 
life – with respect to hearing – of patients undergoing chemo­
therapy is, therefore, an important issue.
Most gynaecological tumours are treated with surgery, 
 followed by adjunct chemotherapy, with or without radio­
therapy. The chemotherapeutic agents used in the treatment 
of these gynaecological patients are platinum­based and non­
platinum­based analogue agents. Platinum analogues such as 
cisplatin and carboplatin are effective antineoplastic agents. 
Unfortunately, various reports have associated these agents 
with toxicities, especially when high doses are administered or 
when the patients have been previously primed with chemo­
therapy. Cisplatin is the most ototoxic drug known [4, 5]. 
High­dose carboplatin can also induce auditory dysfunction 
with a clinical picture that is roughly similar to cisplatinum­
containing chemotherapy [6, 7]. The toxicity of these plati­
num­based agents has been demonstrated to be dose limiting 
[7, 8]. It has also been shown to worsen the hearing threshold 
with a background disability of hearing loss [9]. Reports on 
the adverse effect of platinum analogues on the hearing func­
tion of women with gynaecological conditions are not com­
mon in the literature and are contradictory; some studies have 
reported no significant audiometric changes [10], whereas 
others described high­frequency hearing loss [4, 11].
There are few studies on the effect of other non­platinum 
analogue­based chemotherapeutic agents on hearing [12–14]. 
This study was, therefore, performed to assess the auditory 
function of gynaecological tumour patients who had received 
platinum analogue­ and non­platinum analogue­based chemo­
therapeutic agents to determine whether the ototoxicity side 
effect of the chemotherapeutic agents were experienced by 
these patients. We also investigated the non­platinum­based 
chemotherapeutic agents mostly employed in gynaecological 
cancers for their auditory side effects.
Patients and Methods
Patients
This was a prospective hospital­based study of 87 consecutive patients 
who had undergone chemotherapy for gynaecological malignancies. 
 Approval to conduct the study was obtained from Ethics Committee of 
the Faculty of Medicine at the Technical University of Munich in Ger­
many (No. 1677/06). All the study patients gave written informed consent. 
The type of chemotherapy regimen received by individual patients was 
determined by the primary managing oncologist. There was no record of 
any patient being lost to follow­up; each patient participated in the study 
until 3 months after completion of the chemotherapy.
Questionnaire
A structured questionnaire was used to collect essential clinical 
data, which included the patient’s age, menopause, tumour diagnosis, 
 previous malignancy, previous chemotherapy and current surgical and/or 
chemotherapy regimen. Data on hearing loss, tinnitus, vertigo, family 
 history of hearing loss, hearing aids, previous history of ear surgery, use 
of non­ cytotoxic medication known to induce hearing loss and history 
of other medical diseases such as rhinosinusitis, otitis media, liver or 
renal diseases, hyperactivity or hypoactivity of the thyroid gland, diabetes 
mellitus, high blood pressure and neurological disorders were also 
collected. 
Subjective Assessment of Hearing Function
The hearing function of each patient was subjectively assessed 
before chemotherapy and 3 months after its completion. A visual 
 analogue scale (range 0–100) was used, where 0–20 represented very 
poor, 30–40 poor, 50–60 good, 70–80 very good and 90–100 excellent. 
Subjective assessments of vertigo, tinnitus and ear pressure were also 
 performed on the same scale. The patients’ ears were clinically examined 
before audio metric testing was performed; any ear wax found was 
removed.
Audiometry
Audiometric evaluations (threshold) were obtained for each ear 
at frequencies between 250 and 8,000 Hz. Measurements were taken 
using a pure tone­screening audiometer ST 3 (Audio­Med, Braun­
schweig, Germany). Both air and bone conduction tests were performed 
in a sound proof room separately on both ears. Each patient’s hearing 
was tested 4 times: before (0 weeks) and during chemotherapy (9 weeks), 
and  immediately after (18 weeks), and 3 months after (30 weeks) comple­
tion. The difference in hearing threshold was considered clinically 
 relevant if there was an average loss of pure tone of at least 10 dB com­
pared to the hearing threshold on audiograms taken before starting 
chemotherapy.
Statistical Analysis
Statistical analysis was performed using R 2.11.1 (R Foundation for 
Statistical Computing, Vienna, Austria). To compare patients’ hearing 
function, the areas under the threshold curves (at 500–2000 and 6000–
8000 Hz) were calculated. The areas were tested for differences between 
subgroups using a Mann­Whitney U test. The significance level was set 
at 0.005.
Results
Patients
The age of the patients ranged from 32 to 71 years (mean 
53.5 ± 10.5 years); 61 (70%) were older than 45 years. Of the 
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patients, 73 (83.9%) had undergone primary surgical treat­
ment. The mean interval between surgery and first audiomet­
ric testing was 34.5 ± 17.5 days. All these patients received 
adjuvant chemotherapy. The remaining 14 (16.1%) patients 
had only core biopsy for histological diagnosis before com­
mencing primary chemotherapy. 11 (13%) patients had a 
 history of prior chemotherapy for other malignancies. No 
 patients had any relevant associated co­morbidities, such as 
rhinosinusitis, otitis media, liver or renal problems, hyper­
activity or hypoactivity of the thyroid gland, diabetes mellitus, 
high blood pressure or neurological disorders. The mean 
height of patients was 165.4 ± 5.0 cm and and the mean weight 
67.2 ± 11.4 kg. The clinico­pathological characteristics and 
chemotherapy regimens received by the patients are shown in 
table 1.
Subjective Assessment
The subjective gradings (on a visual analogue score of 
0–100) of hearing function, presence of tinnitus, vertigo and a 
feeling of ear pressure for the patients before chemotherapy 
and 3 months after completion are shown in table 2. The 
scores for hearing function or preservation and perception of 
noise in the ear (tinnitus) by the patients before and 3 months 
after chemotherapy were similar. However, a few patients ex­
perienced vertigo and perception of ear pressure 3 months 
after chemotherapy (table 2). Immediately after completion 
of chemotherapy, on the visual analogue scale score of 0–100, 
only a few patients perceived reduction in their hearing (aver­
age 16.8 ± 29.3), experienced new tinnitus (9.4 ± 23.8), vertigo 
(18.5 ± 30.9) or ear pressure (7.1 ± 19.2).
Audiometric Results
There were no clinically relevant differences of up to 10 dB 
loss, for any of the patients, between the hearing threshold 
before the start, during (9 weeks), immediately after 
(18 weeks), and up to 3 months after completion of chemo­
therapy (fig. 1). Comparing the hearing threshold of the pa­
tients receiving platinum analogue­based chemotherapy with 
those for patients receiving non­platinum analogue­based 
chemotherapy, no significant differences were found in hear­
ing threshold at any time during the study period (table 3). 
Looking at the audiogram for cisplatin­ and carboplatin­
treated patients, the hearing threshold had not worsened by 
3 months after completion of treatment (fig. 2). In the non­
platinum­based group, there was also no observed diminished 
Table 1. Clinico­pathological characteristics and chemotherapy regimen 
in the patients 
Characteristics n %
Total number of patients 87
Histological diagnosis
Breast cancer 69 79
Ovarian cancer 12 14
Cervical cancer  4  5
Endometrial cancer  1  1
Vulva cancer  1  1
Secondary malignancy 11 13
Breast cancer  4  6
Ovarian cancer  1  1
Cervical cancer  1  1
Endometrial cancer  1  1
Vulva cancer  1  1
Chronic lymphocytic leukaemia  1  1
Hodgkin disease  2  2
Chemotherapy regimen
Cyclophosphamide, methotrexate, fluorouracil  4  5
Anthracycline containing* 20 23
Anthracycline and taxane containing** 39 45
Cisplatin  5  6
Carboplatin +/­ paclitaxel 19 21
*Fluorouracil, epirubicin and cyclophosphamide.
**Fluorouracil, epirubicin, and cyclophosphamide/docetaxel;  
docetaxel monotherapy; docetaxel, doxorubicin, and cyclophosphamide; 
dose­dense epirubicin, paclitaxel, and cyclophosphamide; or epirubicin, 
paclitaxel, cyclophosphamide, and capecitabine (German Adjuvant 
 Intergroup Node­Positive Study).
Table 2. The average score of the subjective assessments of the patients’ 
hearing function, tinnitus, vertigo and feeling of pressure within the 
ear on visual analogue scale before commencement and 3 months after 
completion of chemotherapy
Before chemotherapy 3 months after  
chemotherapy
Hearing 83.0 ± 17.2 84.8 ± 16.9
Tinnitus 10.5 ± 25.4  9.4 ± 23.8
Vertigo  4.9 ± 12.4 18.5 ± 30.9
Ear pressure  4.9 ± 16.4  7.1 ± 19.2
Fig. 1. Comparison of hearing thresholds of gynaecological patients who 
received chemotherapy before, during, immediately after, and 3 months 
after completion of chemotherapy.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:3
8:
00
 P
M
Breast Care 2013;8:276–281Hearing Function in Gynaecologic Tumour 
 Patients Undergoing Chemotherapy
279
hearing threshold during or after chemotherapy (fig. 3). This 
was also the case for patients who had previous exposure to 
chemotherapy with no reduction in hearing threshold seen on 
the audiograms (table 3). No significant differences in the 
hearing threshold were found for the various tumour diagno­
ses (table 3). When the hearing thresholds obtained before 
chemotherapy for patients aged 45 years or younger were 
compared to those for patients older than 45 years, there was 
a significant difference in the hearing threshold at 6 and 
8 KHz, and this difference was observed in the subsequent 
 audiometric tests. The older patients had worse hearing 
threshold for the high frequencies (table 3). However, the 
comparison of hearing thresholds of patients (old or young 
group) at 9 weeks, 18 weeks or 3 months after completion of 
chemotherapy did not show any significant differences.
Fig. 2. Comparison of hearing  
thresholds  between gynaecological  
patients who had  received cisplatin  
and carboplatin chemotherapy.
p value,  
left ear
p value,  
right ear
500–2000 Hz
Platinum versus non­platinum analogue based chemotherapy
During chemotherapy 0.8798 0.5174
After 0.5352 0.4449
3 months after 0.009447 0.03019
Cisplatin versus carboplatin group
During chemotherapy 0.6147 0.7236
After 1 0.5933
3 months after 0.1030 0.7332
Previous versus no previous exposure to chemotherapy
During chemotherapy 0.04093 0.1957
After 0.8602 0.3219
3 months after 0.5013 0.3061
Breast cancer versus ovarian cancer group
During chemotherapy 0.7139 0.6181
After 0.8828 0.8063
3 months after 0.7127 0.8504
Young versus old group
During chemotherapy 0.02112 0.01247
After 0.01231 0.01294
3 months after 0.6336 0.2577
6000–8000 Hz
Platinum versus non­platinum analogue based chemotherapy
During chemotherapy 0.1735 0.2346
After 0.2747 0.06419
3 months after 0.9409 0.5731
Cisplatin versus carboplatin group
During chemotherapy 0.8008 0.6856
After 0.1618 0.07397
3 months after 0.2030 1
Previous versus no previous exposure to chemotherapy
During chemotherapy 0.9108 0.7901
After 0.4178 0.6229
3 months after 0.4672 0.9441
Breast cancer versus ovarian cancer group
During chemotherapy 0.1645 0.3134
After 0.4178 0.6229
3 months after 0.4672 0.9441
Young versus old group
During chemotherapy 0.00003778 0.0004689
After 0.0002621 0.00003951
3 months after 0.01841 0.02057
Table 3. Comparison of patients’ hearing 
function from calculations of the areas under 
the threshold curves (500–2000 and 6000–
8000 Hz). The areas were tested for differences 
between subgroups using Mann­Whitney  
U test. The significance level was set at 0.005
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Discussion
At 3 months after chemotherapy, the 87 women with gyn­
aecological malignancies, who had been treated with chemo­
therapeutic agents, subjectively rated their hearing functions 
to be very good to excellent. To substantiate the subjective 
reports of the patients, the hearing function was tested with 
pure tone audiometry before, during, directly after, and 
3 months after chemotherapy. No significant audiometric 
change in the speech hearing frequency (0.5–2 KHz) was ob­
served. This study showed that speech hearing frequencies 
were not significantly affected by the chemotherapeutic 
agents in the gynaecological patients followed in this study. 
This finding is in agreement with that of Jillella et al. [10], who 
did not observe clinical evidence of hearing impairment in any 
breast cancer patients treated with chemotherapy (cyclophos­
phamide, thiotepa and carboplatin). Although only 27% of 
the patients in this study received platinum­based chemother­
apy, our findings also concurred with those of Laurell et al. 
[11], who did not observe a single case of significant change in 
the hearing frequency range of 0.5–2 KHz in a larger gynaeco­
logical cancer population treated with cisplatin. Waters et al. 
[4] reported that the ototoxic effects of cisplatin, which in­
cluded tinnitus and hearing loss in the speech frequency 
range, were associated with the administration of high 
 dosages over a short period of time. Low­dose short­treat­
ment regimens with either monthly administration of cisplatin 
or administration in block have been demonstrated to have 
low ototoxicity [4, 11]. The ototoxicity induced by carboplatin 
has been demonstrated to be roughly similar to that of cis­
platin when used in high dose [6, 7]. The toxicity of carbo­
platin is dose limiting. Although the conventional dose of 
350–400 mg/m2 per body surface area every 4 weeks is usually 
given, the recommendation for carboplatin administration, 
according to the Calvert formula, is: target AUC × (GFR+25). 
In this study the patients treated with platinum­based chemo­
therapy received either 40–50 mg/m2 of cisplatin or AUC5 of 
carbo platin and this might have accounted for the audio­
metric findings in these patients.
Hearing loss for high frequencies has been associated with 
high­dose platinum­based chemotherapeutic agents [11, 15]. 
Laurell et al. [11] reported high­frequency hearing loss in 
22% of their patients in their older age group but did not find 
pretreatment with chemotherapy as a predictor for ototoxic 
change. Cisplatin ototoxicity has been demonstrated to cause 
an initial high­frequency hearing loss and the continued use 
of the drug has been shown to result in low­frequency hear­
ing loss [16, 17]. High­frequency hearing loss can impact neg­
atively on educational achievement, socio­emotional devel­
opment, and quality of life. It was observed in this study that 
patients older than 45 years had a significantly high­frequency 
(6 and 8 KHz) hearing loss. This was observed in the audio­
metric tests of most of these patients before commencement, 
during, immediately after and 3 months after completion of 
the chemotherapy. Presbyacusis (high­frequency hearing loss) 
commonly occurs in older patients [18]. We did not find that 
chemotherapy led to a significant difference in the hearing 
threshold between older and younger groups.
Only 11 patients (13%) in this study had history of prior 
chemotherapy for other malignancies. For these patients, no 
significant difference in their hearing threshold before, during 
and after completion of chemotherapy was found when com­
pared to patients without a history of previous chemotherapy.
In this study 23% of the patients received an FEC (fluoro­
uracil, epirubicin and cyclophosphamide) regimen, either alone 
or in combination with anthracycline, but no audiometric 
Fig. 3. Hearing thresholds of gynaecological 
patients who received non­platinum analogue­
based chemotherapy.
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References
changes at either speech frequencies or high frequencies were 
observed. In contrast, Jenkins et al. [13] reported atypical 
hearing loss in 9 of 16 women (64%) with breast cancer 
treated with FEC chemotherapy regimen. However, there 
was no clear statement on whether this observation had to do 
with FEC. Taxanes are new groups of anti­neoplastic agents 
used for chemotherapy and 45% of the patients in this study 
were treated with this medication. No significant audiometric 
changes were observed at either speech or high frequencies 
on the audiogram of these patients throughout the period of 
the study. This finding is in accordance with the work by 
Sarafraz et al. [12], who reported no audiovestibular side ef­
fects in 103 patients with either breast or ovarian cancers 
treated with taxanes during, and immediately after comple­
tion of, chemotherapy. There was also no difference at 
3 months after completion of chemotherapy in this study.
The ototoxicity effects of chemotherapy are reflected not 
only in hearing loss but also in the clinical manifestations of 
 sensory cochlea­vestibular complaints of tinnitus and ver­
tigo. Although the subjective assessment in this study 
showed that the patients had no change in their hearing or in 
tinnitus 3 months after completion of chemotherapy, vertigo 
was experienced in more of these patients with 18.5±30.9 on 
a visual  analogue scale compared to 4.9 ± 12.4 before chemo­
therapy (0 = no vertigo, 100 = strong vertigo) as shown in 
table 2. This supports the evidence that chemotherapeutic 
agents may also have a toxic effect on the vestibular system. 
Benign paroxysmal positional nystagmus (BPPN) is the most 
common cause of  vertigo in the general population and 
Black et al. [19] have demonstrated an increased incidence 
of BPPN in patients  receiving ototoxic medications. Al­
though this study’s primary interest was on hearing, this 
 observed finding of subjective vertigo in some patients in 
this study would be an area to investigate further in future.
Al­Khatib et al. [20] in their study of children treated with 
platinum chemotherapy have reported the importance of 
long­term follow­up of these patients because ototoxicity can 
newly present or become worse years after completion of the 
therapy. Routine monitoring of patients on chemotherapy 
for early detection of signs of ototoxicity and initiation of 
preventive measures were suggested methods in patients 
being treated with ototoxic agent. However, the present 
study has shown that, in gynaecological patients, routine 
monitoring of hearing of  cancer patients after each cycle of 
chemotherapy received is  unnecessary up to a period of 
3 months after completion of chemotherapy. This would 
help to minimise patients’ financial commitments and fre­
quent hospital visits.
In conclusion, deterioration of hearing function is uncom­
mon in gynaecological patients treated with either platinum­
based or non­platinum­based chemotherapy. Hence, routine 
audiometric test in these patients up to 3 months after com­
pletion of chemotherapy is not necessary.
Disclosure Statement
The authors have no conflicts of interest to declare.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:3
8:
00
 P
M
